Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities

Stem Cell Res Ther. 2021 Mar 3;12(1):161. doi: 10.1186/s13287-021-02212-0.

Abstract

Premature ovarian failure (POF) is one of the common disorders found in women leading to 1% female infertility. Clinical features of POF are hypoestrogenism or estrogen deficiency, increased gonadotropin level, and, most importantly, amenorrhea. With the development of regenerative medicine, human mesenchymal stem cell (hMSC) therapy brings new prospects for POF. This study aimed to describe the types of MSCs currently available for POF therapy, their biological characteristics, and their mechanism of action. It reviewed the latest findings on POF to provide the theoretical basis for further investigation and clinical therapy.

Keywords: Mesenchymal stem cells; Ovarian function; Premature ovarian failure.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Female
  • Humans
  • Immunologic Factors
  • Mesenchymal Stem Cells*
  • Primary Ovarian Insufficiency* / therapy
  • Regenerative Medicine

Substances

  • Immunologic Factors